JASON CROWL: Open Payments
NPI 1518520923 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$923 in 40 payments from 13 companies in 2025. Trend: 2023 $545 · 2024 $1,193 · 2025 $923
Food & beverage: $855Education: $69
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $219 |
| Astellas Pharma US Inc | 5 | $135 |
| AstraZeneca Pharmaceuticals LP | 7 | $135 |
| ABBVIE INC. | 3 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Lilly USA, LLC | 2 | $62 |
| PFIZER INC. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Amgen Inc. | 2 | $42 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
Products named: Ozempic, VRAYLAR, Veozah, REXULTI, MOUNJARO, FARXIGA, VOQUEZNA, FASENRA.
Industry payments across MD — which companies pay providers there.
